ArticleCytotechnology2021
MiR-522-3p inhibits proliferation and activation by regulating the expression of SLC31A1 in T cells.
Article in Cytotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 7 citations in OpenAlex.
- Cuproptosis-related Gene Signatures and Immunological Characterization in Sepsis-associated Acute Lung Injury.Combinatorial chemistry & high throughput screening · 2025Article
- Blocking lactate regulation of the Grhl2/SLC31A1 axis inhibits trophoblast cuproptosis and preeclampsia development.Journal of assisted reproduction and genetics · 2024Article
- The intricate dance of non-coding RNAs in myasthenia gravis pathogenesis and treatment.Frontiers in immunology · 2024Review
- Identification and immuno-infiltration analysis of cuproptosis regulators in human spermatogenic dysfunction.Frontiers in genetics · 2023Article
- A Review on the Role of Non-Coding RNAs in the Pathogenesis of Myasthenia Gravis.International journal of molecular sciences · 2021Review
Corrections and comments
- Retraction · 2024-09-19Lack of IRB/IACUC Approval and/or Compliance ·
- Retracted
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated the role of miR-522-3p in thymoma-associated myasthenia gravis (TAMG), and the mechanism of action in T cells. The miR-522-3p expression in normal serum, non-thymoma MG patient serum and TAMG patient serum and tissues was detected by quantitative real-time PCR (qRT-PCR), respectively. We assessed miR-522-3p expression in Jurkat cells and human CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.